RxDoctor Payments Data

Robert Hamilton Iii, MD

Neurology · Aurora, CONPI 1295115178

Payments from drug & device makers

$2,369in general payments, 2019–2025

Across 102 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$669
  • AbbVie$542
  • Pfizer$351
  • UCB, Inc.$248
  • Biohaven Pharmaceuticals, Inc.$131
  • Biohaven Pharmaceutical Holding Company Ltd.$69
  • plus $359 from 12 others

What the payments were for

  • Travel & lodging$37616%
  • Food & beverage$1,96083%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,369 in reported general payments places this provider in the 55th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$40,462
Medicare patients
145
Services billed
1,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam75$123,524
XcopriCenobamate57$72,986
Nurtec OdtRimegepant Sulfate52$66,417
FycompaPerampanel45$57,288
NayzilamMidazolam20$35,744
EpidiolexCannabidiol (Cbd)11$35,601
Emgality PenGalcanezumab-Gnlm42$32,636
QuliptaAtogepant24$27,642
Lacosamide116$25,780
Lamotrigine ErLamotrigine20$15,089
Ajovy AutoinjectorFremanezumab-Vfrm13$13,912
Aimovig AutoinjectorErenumab-Aooe14$10,122
Levetiracetam229$9,790
Carbamazepine ErCarbamazepine40$6,228
Oxcarbazepine57$5,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$248$159,26895 claims
SK Life Science, Inc.Xcopri$13$72,98657 claims
PfizerNurtec Odt$351$66,41752 claims
Eisai Inc.Fycompa$52$57,28845 claims
AbbVieQulipta$542$27,64224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 334 neurology providers in Colorado.

Other neurology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →